---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-269415"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:20:39.049757+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Scott Myers resigns from Viridian board; company adopts amended bylaws effective Nov 1, 2023

## Summary
- Scott Myers resigned from the board effective Oct 29, 2023; departure not due to any disagreement with the company.
- Board adopted Third Amended and Restated Bylaws effective Nov 1, 2023.
- Bylaws modify notice period required to call a special meeting of the Board.

## SEC filing metadata
- accession: 0001193125-23-269415
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312523269415/0001193125-23-269415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312523269415/d557083d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-269415
- JSON: https://secwatch.observer/filing/0001193125-23-269415.json
- Plain text: https://secwatch.observer/filing/0001193125-23-269415.txt

## Key facts
- Executive change
  Scott Myers resigned as director at Viridian Therapeutics, Inc.\DE.
  - Action: resigned
  - Role: director
  source text: On October 29, 2023, Scott Myers resigned as a member of the board of directors (the "Board") of Viridian Therapeutics, Inc. (the "Company"), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523269415/0001193125-23-269415-index.htm
- Governance Changes
  Viridian Therapeutics, Inc.\DE: The Board adopted the Third Amended and Restated Bylaws, modifying the notice period required to call a special meeting of the Board (effective 2023-11-01).
  - Change: bylaw amendment
  - Effective: 2023-11-01
  source text: Effective November 1, 2023, the Board adopted the Third Amended and Restated Bylaws of the Company (the “Bylaws”). The Bylaws, among other things, modify the notice period required to call a special meeting of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523269415/0001193125-23-269415-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.